INVEGA SUSTENNA® Common Dosing and Administration Topics
Switching from Other Antipsychotics
From Oral RISPERDAL® to INVEGA SUSTENNA® - General Overview
Consistent with the INVEGA SUSTENNA® Prescribing Information:
- There are no systematically collected data to specifically address switching patients with schizoaffective disorder from other antipsychotics to INVEGA SUSTENNA®, or concerning concomitant administration with other antipsychotics.
- Previous oral antipsychotics can be gradually discontinued at the time of initiation of treatment with INVEGA SUSTENNA®.
- Recommended initiation of INVEGA SUSTENNA® is with a dose of 234 mg followed by 156 mg one week later, both administered in the deltoid muscle. Patients stabilized on RISPERDAL® tablets can attain similar steady-state exposure with INVEGA SUSTENNA® as depicted in Table. The INVEGA SUSTENNA® Prescribing Information does not specifically address conversion of RISPERDAL® tablets to INVEGA SUSTENNA®. This information is based on pharmacokinetic (PK) modeling performed to compare steady-state exposure during maintenance treatment between risperidone tablets and INVEGA SUSTENNA® (after both the 234 mg/156 mg deltoid starting doses).*
Table: Doses of RISPERDAL® and INVEGA SUSTENNA® Needed To Attain Similar Steady-State Palliperidone Exposure During Maintenance Treatment*
|Formulation||RISPERDAL® Tablet||INVEGA SUSTENNA® Injection|
|Dosing Frequency||Total Daily Dose||Every 4 weeks|
*Russu A, Sliwa JK, Ravestijn P, et al. Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations. Int J Clin Pract. 2018;e13089.
For illustrative displays of this dosing scenario, please click the link(s) below.